AstraZeneca
Big pharma teams with government on genomic research
March 27, 2015Research and Development, Sales and Marketing AbbVie, Alexion Pharmaceuticals, AstraZeneca, Biogen, Cameron, Dimension Therapeutics, GSK, Genomic, Genomics england, Helomics, Roche, Takeda, UCB, UK, genomes
Ten firms will partner up with Genomics England to develop new diagnostics and treatments for people with rare diseases and …
AstraZeneca and Harvard team up for diabetes research
March 25, 2015Research and Development, Sales and Marketing AZ, AstraZeneca, Havard, cardiovascular, diabetes, metabolic
AstraZeneca is to work with Harvard University’s department of stem cell and regenerative biology to develop new treatments in diabetes. …
GSK and Theravance see FDA nod for asthma indication
March 20, 2015Sales and Marketing Advair, AstraZeneca, Dulera, FDA, Foradil, GSK, Merck, Symbicort, Theravance, asthma, breo, budesonide/formoterol fumarate dihydratem, ellipta, fluticasone propionate, formoterol fumarate, mometasone/formoterol
An FDA panel has recommended the approval of asthma treatment Breo Ellipta in adults – but voted against supporting its …
AstraZeneca and Daiichi team up for constipation drug
March 19, 2015Sales and Marketing AstraZeneca, Daiichi, Movantik, constipation, naloxegol, oic
AstraZeneca and Daiichi Sankyo have signed a deal worth around $825 million to jointly commercialise constipation drug Movantik in the …
AstraZeneca buoyed by late-stage trial success
March 18, 2015Sales and Marketing AstraZeneca, copd. asthma, formoterol fumarate, glycopyrronium, ptoo3, respiratory
AstraZeneca’s investigational respiratory drug has posted positive results in a Phase III trial in people with COPD, having found it …
Mixed results for AstraZeneca in high-profile Brilinta study
March 17, 2015Sales and Marketing American College of Cardiology, AstraZeneca, Brilinta, EMA, FDA, ticagrelor
Experts say AstraZeneca is at risk of ‘diminishing returns’ in the clinical advantages of its blood-thinning drug Brilinta, after it …
Merck Serono bets on precision medicine
March 11, 2015Sales and Marketing AstraZeneca, Diagnostics, FDA, Illumina, Merck Serono, opexa, personalised
Merck Serono is looking to expand further into personalised medicine as the company enters into an agreement with Illumina to …
AstraZeneca completes respiratory deal with Actavis
March 3, 2015Research and Development, Sales and Marketing Actavis, AstraZeneca, COPD, Daliresp, Tudorza Pressair, aclidinium bromide inhalation powder, respiratory, roflumilast
AstraZeneca has completed its acquisition of Dublin-headquartered firm Actavis with its branded respiratory portfolio deal worth $700 million. The agreement …
Actavis and AZ see FDA approval for ‘superbug’ drug
February 27, 2015Research and Development, Sales and Marketing Actavis, AstraZeneca, Avycaz, FDA, US, ceftazidime/avibactam
Actavis and AstraZeneca’s combo ‘superbug’ drug Avycaz has been shown the green light to treat patients with complicated intra-abdominal infections …
AstraZeneca enters autoimmune diseases pact with Orca
February 25, 2015Research and Development, Sales and Marketing AstraZeneca, autoimmune, orca, orphan nuclear receptor gamma inhibitors, psoriasis, retinoic
AstraZeneca has signed a three-year research deal with the UK-based biotech firm Orca to develop treatments for autoimmune diseases. The …
UK pharma commits at least ‘one code breach a week’
February 18, 2015Medical Communications, Sales and Marketing ABPI, AstraZeneca, Bayer, Eli Lilly, GSK, Novartis, Novo Nordisk, PMCPA, Pfizer, code
Pharma companies commit unethical marketing practices on average more than once a week in the UK academic analysis has found. …
Several board changes at AstraZeneca
February 17, 2015Sales and Marketing AstraZeneca, Bruce Burlington, Cornelia Bargmann, Graham Chipchase, Rudy Markham
AstraZeneca is conducting a boardroom overhaul as it announces non-executive board changes and retirements ahead of its annual meeting in …
AstraZeneca loses US Pulmicort patent
February 16, 2015Sales and Marketing AstraZeneca, Budesonide Inhalation Suspension, asthma, pulmicourt, respiratory
British drugmaker AstraZeneca has been dealt a blow by the courts in the US, after a district judge ruled its …
AstraZeneca looks for revenue boost via Actavis buy
February 6, 2015Sales and Marketing Actavis, AstraZeneca, Brilinta, Forxiga, diabetes, fourth quarter, q4
AstraZeneca recorded a dip in revenue in the last quarter of 2014 and is looking to ramp up its respiratory …
AstraZeneca dives into gene editing
January 29, 2015Research and Development, Sales and Marketing AstraZeneca, Intellia Therapetics, Novartis, Thermo Fisher Scientific, Wellcome Trust Sanger Institute in Cambridge, Whitehead, broad institute, crispr, the Innovative Genomics Initiative in California
AstraZeneca is looking to harness the power of a pioneering genome-editing tool in a series of new collaborations. The UK …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
